Table 1 Clinical characteristics of ER-positive patients with Fulvestrant usage (n = 136)
Covariates | Level | All patients (n = 136) | Fulvestrant usage | p-value†| ||
|---|---|---|---|---|---|---|
First line (n = 17) | Second line (n = 61) | ≥ Third line (n = 58) | ||||
Age at diagnosis (years) |  | 46.67 ± 9.66, 46 (39, 55) | 48.26 ± 8.62, 48.5 (39.5, 56) | 48.19 ± 10.04, 47 (39, 58) | 44.69 ± 9.07, 44 (39, 50) | 0.07 |
Age at FX usage (years) |  | 53.37 ± 9.52, 53 (47, 62) | 56.63 ± 7.16, 55.5 (52.5, 63) | 54.63 ± 9.74, 55.5 (47, 62) | 51.19 ± 9.27, 51 (45, 64) | 0.01 |
Weight |  | 58.67 ± 12.37, 58 (54, 62) | 56.33 ± 2.88, 56.5 (55, 58) | 57.21 ± 7.73, 57 (53, 61) | 60.10 ± 15.94, 58 (54, 62) | 0.27 |
ER | Negative | 2 (1.47%) | 0 (0%) | 2 (3.28%) | 0 (0%) | 0.90 |
|  | 1%–10% | 3 (2.21%) | 0 (0%) | 1 (1.64%) | 2 (3.45%) |  |
|  | 10%–50% | 11 (8.09%) | 0 (0%) | 6 (9.84%) | 5 (8.62%) |  |
|  | 50%–80% | 37 (27.21%) | 5 (29.41%) | 16 (26.23%) | 16 (27.59%) |  |
|  | 80%–100% | 25 (18.38%) | 5 (29.41%) | 10 (16.39%) | 10 (17.24%) |  |
| Â | Positive unknown % | 58 (42.65%) | 7 (41.18%) | 26 (42.62%) | 25 (43.10%) | Â |
PR | Negative | 18 (13.24%) | 3 (17.65%) | 6 (9.84%) | 9 (15.52%) | 0.52 |
| Â | Positive | 118 (86.76%) | 14 (82.35%) | 55 (90.16%) | 49 (84.48%) | Â |
HER2 | Positive | 13 (9.56%) | 3 (17.65%) | 3 (4.92%) | 7 (12.07%) | 0.17 |
| Â | Negative | 123 (90.44%) | 14 (82.35%) | 58 (95.08%) | 51 (87.93%) | Â |
Nuclear or histological grade | 2 | 35 (25.74%) | 3 (17.65%) | 18 (29.51%) | 14 (24.14%) | 0.84 |
3 | 51 (37.50%) | 6 (35.29%) | 22 (36.07%) | 23 (39.66%) | Â | |
| Â | Unknown | 50 (36.76%) | 8 (47.06%) | 21 (34.43%) | 21 (36.21%) | Â |
Stage | I | 15 (11.03%) | 1 (5.88%) | 5 (8.20%) | 9 (15.52%) | 0.35 |
| Â | II | 35 (25.74%) | 5 (29.41%) | 17 (27.87%) | 13 (22.41%) | Â |
| Â | III | 53 (38.97%) | 4 (7.55%) | 26 (42.62%) | 23 (39.66%) | Â |
| Â | IV | 2 (1.47%) | 1 (5.88%) | 1 (1.64%) | 0 (0%) | Â |
| Â | Unknown | 31 (22.79%) | 6 (35.29%) | 12 (19.67%) | 13 (22.41%) | Â |
Menopause | Natural menupause | 83 (61.03%) | 13 (76.47%) | 41 (67.12%) | 29 (50.00%) | 0.02 |
|  | OFS (OFS + surgery) | 24 (17.65%) | 4 (23.53%) | 10 (16.39%) | 10 (17.24%) |  |
| Â | Surgery | 29 (21.32%) | 0 (0%) | 10 (26.39%) | 19 (32.76%) | Â |
Treatment of primary diagnosis | Primary site surgery | 134 (98.53%) | 17 (100%) | 60 (98.36%) | 57 (98.28%) | 0.49 |
Primary site radiation | 52 (38.24%) | 5 (29.41%) | 23 (37.70%) | 24 (41.38%) | 0.67 | |
| Â | Chemotherapy | 117 (86.03%) | 14 (82.35%) | 52 (85.25%) | 51 (87.93%) | 0.78 |
| Â | Endocrine therapy | 100 (73.53%) | 13 (76.47%) | 40 (65.57%) | 47 (81.03%) | 0.15 |
Treatment after relapse or metastasis | Radiation | 21 (15.44%) | 0 (0%) | 10 (16.39%) | 11 (18.97%) | 0.15 |
Chemotherapy | 80 (58.82%) | 6 (35.29%) | 28 (45.90%) | 46 (79.31%) | < 0.0001 | |
DFS (years)* |  | 4.86 ± 3.38, 4.24 (2.48, 6.96) | 8.28 ± 3.94, 7.93 (5.89, 10.64) | 5.01 ± 3.21, 4.69 (2.84, 7.36) | 3.61 ± 2.57, 3.07 (2.00, 5.10) | < 0.0001 |
Metastatic sites | Lymph nodes | 53 (38.97%) | 10 (58.82%) | 24 (39.34%) | 19 (32.76%) | 0.17 |
| Â | Bone | 93 (68.38%) | 8 (47.06%) | 45 (73.77%) | 40 (68.97%) | 0.12 |
| Â | Visceral | 68 (50.00%) | 6 (35.29%) | 30 (49.18%) | 32 (55.17%) | 0.01 |